Raynaud’s Disease Market | Raynaud’s Disease Market Trends 2030

1. Raynaud’s phenomenon (RP) is caused by episodic vasospasm and ischemia of the extremities in response to cold or emotional stimuli, which result in a characteristic triphasic color change in extremities usually fingers or toes from white, to blue, to red. RP is usually seen in distal digits but may also involve nose, ears and tongue. Raynaud’s phenomenon may be distinguished as primary, which is the occurrence of the vasospasm alone, with no association with another illness and Secondary caused byan underlying condition like autoimmune disorders such as rheumatoid arthritis, scleroderma, systemic lupus erythematosus and others. DelveInsight's "Raynaud’s Disease - Market Insights, Epidemiology, and Market Forecast- 2030" report delivers an in-depth understanding of the Raynaud’s Disease, historical and forecasted epidemiology as well as the Raynaud’s Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Raynaud’s Disease market report provides current treatment practices, emerging drugs, Raynaud’s Disease market share of the individual therapies, current and forecasted Raynaud’s Disease market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Raynaud’s Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Geography Covered    The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Request for sample pages: https://www.delveinsight.com/sample-request/raynauds-disease- market Raynaud’s Disease Disease Understanding and Treatment Algorithm The DelveInsight Raynaud’s Disease market report gives a thorough understanding of the Raynaud’s Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Raynaud’s Disease Epidemiology The Raynaud’s Disease epidemiology divisionprovide insights about historical and current Raynaud’s Diseasepatient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Key Findings:  The prevalence of Raynaud’s phenomenon (RP) in most studies of the general population is between 3 and 5 %. Primary RP accounts for 80–90 % of cases.  According to the review of literature, the prevalence of primary Raynaud’s varies among different populations; from 4.9–20.1% in women to 3.8–13.5% in men whereas the frequency of secondary Raynaud’s depends on the underlying disorder.

2.  Primary Raynaud’s affects more women than men, generally under the age of 30 and secondary Raynaud’s age at onset is > 30. Raynaud’s Disease Drug Chapters The dedicated research with advances in the understanding of Raynaud’s phenomenon, laid the footsteps of various therapies with the key role of global players such as Seelos Therapeutics, Bayer, Allergan and others in developing potential therapies for Raynaud’s phenomenon at the global level. Launch of emerging therapies, such as RayVa (Seelos Therapeutics), and others are expected to significantly impact the treatment scenario of Raynaud’s phenomenon in the upcoming years 2019-2028. Drug chapter segment of the Raynaud’s Disease report encloses the detailed analysis of Raynaud’s Disease marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Raynaud’s Diseaseclinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Download sample pages: https://www.delveinsight.com/sample-request/raynauds-disease- market Raynaud’s Disease Market Outlook The first step in managing Raynaud’s phenomenon in primary care is lifestyle modification. Such advice can be given to patients while awaiting investigations and referral to secondary care if an underlying cause is suspected. Most people with primary Raynaud’s phenomenon respond well to lifestyle measures and need no further treatment. Patients with secondary Raynaud’s phenomenon require treatment of the underlying disorder. Drug therapy is recommended in patients with secondary Raynaud phenomenon who have severe attacks or if there is evidence of tissue damage such as digital ulcerations. Treating the underlying disease process is most important (e.g., thyroid replacement if there is hypothyroid). The most common medications used for Raynaud’s phenomenon are calcium channel blockers such as amlodipine, nifedipine, felodipine, as well as angiotensin-receptor blockers. These medications act by increasing blood flow to the fingers and toes. For patients with more severe symptoms or who have developed complications such as ulcers on the fingertips, other medications can be used, including sildenafil or prostacyclins. Sometimes, patients are also prescribed other medications that can help improve symptoms, including topical creams, selective-serotonin-reuptake inhibitors (SSRIs), or cholesterol- lowering (statin) medications. The Raynaud’s Disease market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Raynaud’s Diseasemarkettrends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, Raynaud’s Diseasemarket in 7MM is expected to change in the study period 2017-2030. Click here to get free sample pages: https://www.delveinsight.com/sample-request/raynauds- disease-market